ReviewCurrent diabetes reports2017
Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.
Review in Current diabetes reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Treatment of Type 2 diabetes with Tianqi Jiangtang Capsule: A systematic review and meta-analysis of randomized controlled trials.Medicine · 2020Pooled it
- Gc inhibition preserves insulin sensitivity and reduces body weight without loss of muscle mass.JCI insight · 2025Article
- The Ongoing Utility of lipoprotein lipase activity in diagnosing familial Chylomicronemia Syndrome.Biochemistry and biophysics reports · 2025Article
- [Impact of diabetes on cardiovascular risk in patients with dyslipidemia].Archivos de cardiologia de Mexico · 2024Observational
- GWAS of lipids in Greenlanders finds association signals shared with Europeans and reveals an independent PCSK9 association signal.European journal of human genetics : EJHG · 2024Article
- Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Endogenous Protective Factors and Potential Therapeutic Agents for Diabetes-Associated Atherosclerosis.Frontiers in endocrinology · 2022Review
- Diabetic retinopathy risk prediction in patients with type 2 diabetes mellitus using a nomogram model.Frontiers in endocrinology · 2022Article
- Prevalence and Risk Factors for Self-Report Diabetes Mellitus: A Population-Based Study.International journal of environmental research and public health · 2020Article
- Early myocardial injury biomarkers in diabetic hyperlipidemic rats: Impact of 10-dehydrogingerdione and vitamin D3.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- Towards more specific treatment for diabetic dyslipidemia.Current opinion in lipidology · 2018Review
- The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications.International journal of molecular sciences · 2018Review
- A Novel Strategy to Prevent Advanced Atherosclerosis and Lower Blood Glucose in a Mouse Model of Metabolic Syndrome.Diabetes · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis article reviews current knowledge concerning diabetic dyslipidemia and cardiovascular disease (CVD). It reviews strategies to reduce diabetes-associated CVD, including reducing low-density lipoprotein levels, lowering triglycerides, and increasing high-density lipoproteins (HDL). Special considerations, such as the multifactorial chylomicronemia syndrome and partial lipodystrophy, and the role of glucose-lowering strategies in the management of diabetic dyslipidemia are discussed. RECENT
findingsThe strongest evidence to date for reducing CVD in diabetes comes from the use of statins. While triglyceride lowering remains inconclusive, an ongoing trial might provide some finality to this question. The role of increasing HDL remains elusive, and HDL cholesterol appears to be an unsatisfactory metric for monitoring therapy. The use of statins offers the best current way to reduce diabetes-associated CVD. However, several novel and promising approaches for the management of diabetic dyslipidemia aimed at reducing CVD are in the pipeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.